Application of astragalus acid in the preparation of inhibitors of core protease I7L activity and drugs against orthopoxvirus infections

High-throughput drug screening identified urushiol as an inhibitor of the core protease I7L, solving a challenge in the treatment of monkeypox virus. It achieved the dual effects of effectively inhibiting viral replication and alleviating inflammation, providing a safe treatment option.

CN122075461APending Publication Date: 2026-05-26SHANGHAI INSTITUTE OF INFECTIOUS DISEASE & BIOSECURITY
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
SHANGHAI INSTITUTE OF INFECTIOUS DISEASE & BIOSECURITY
Filing Date
2026-04-15
Publication Date
2026-05-26

AI Technical Summary

Technical Problem

Currently, there is a lack of effective vaccines or drugs for the prevention and treatment of monkeypox virus. Existing drugs such as Tecovirimat have not shown significant effects in clinical treatment, and there is an urgent need to develop new and highly effective anti-monkeypox virus drugs.

Method used

High-throughput drug screening technology was used to discover and confirm that urushiol can effectively inhibit the activity of the core protease I7L. Rushiol was developed as an inhibitor of the core protease I7L activity to block viral replication and alleviate inflammatory response, and to prepare an anti-orchioplasmosis virus infection drug.

Benefits of technology

Ascorbic acid inhibits monkeypox virus core protease I7L by 70%, exhibiting significant dual antiviral and anti-inflammatory effects, thus improving the safety and efficiency of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122075461A_ABST
    Figure CN122075461A_ABST
Patent Text Reader

Abstract

This invention discloses the application of urushiol in the preparation of inhibitors of core protease I7L and drugs against orthopoxvirus infections, belonging to the field of biomedical technology. Utilizing high-throughput drug screening technology, this invention, through multiple screenings, obtained urushiol, a small molecule compound capable of efficiently inhibiting core protease I7L. Experiments confirmed that urushiol has an IC50 value of 9.11 μM against monkeypoxvirus core protease I7L, making it suitable for use in the preparation of drugs for the prevention and treatment of monkeypoxvirus. The research results of this invention not only have significant scientific importance for the prevention and treatment of monkeypoxvirus but also provide broad application prospects for addressing the potential threats posed by orthopoxviruses in the future.
Need to check novelty before this filing date? Find Prior Art